PRL Secreting Adenomas in Male Patients

Overview

Journal Pituitary

Specialty Endocrinology

Date 2006 Jan 18

PMID 16411067

Citations 22

Authors

Antonio Ciccarelli

Ermelinda Guerra

Michele De Rosa

Francesco Milone

Stefano Zarrilli

Gaetano Lombardi

Annamaria Colao

Affiliations

Soon will be listed here.

Abstract

Prolactinomas are the most frequent pituitary tumors and their frequency varies with age and sex, occurring most frequently in females between 20-50 yr-old. In men, hyperprolactinaemia is often present for many years without symptoms, as generally the most important symptoms are the decrease in libido and/or sexual potency both underestimated by the majority of the patients. Prolactin (PRL) plays a role in the process of spermatogenesis, and normal serum PRL levels are required for normal testicular function. On the other hand, hyperprolactinaemia has multiple negative effects on the gonadal axis. As a consequences hyperprolactinemic males show alteration of sexual potency and seminal fluid quality. Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.

Citing Articles

Clinical Characteristics of Macroprolactinomas and Response to Medical Therapy.

Tiwari P, Saikia U, Baro A, Bhuyan A Indian J Endocrinol Metab. 2024; 28(3):268-272.

PMID: 39086562 PMC: 11288516. DOI: 10.4103/ijem.ijem_283_23.

Evaluation of Treatment Strategies for Male Prolactin-Secreting Pituitary Neuroendocrine Tumors.

Saito N, Hirai N, Koyahara Y, Sato S, Hiramoto Y, Fujita S Cureus. 2024; 16(2):e54503.

PMID: 38516477 PMC: 10955445. DOI: 10.7759/cureus.54503.

Influence of gender and sexual hormones on outcomes after pituitary surgery: a systematic review and meta-analysis.

Theiler S, Hegetschweiler S, Staartjes V, Spinello A, Brandi G, Regli L Acta Neurochir (Wien). 2023; 165(9):2445-2460.

PMID: 37555999 PMC: 10477253. DOI: 10.1007/s00701-023-05726-z.

Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature.

Yan Z, Lei T Brain Sci. 2022; 12(6).

PMID: 35741681 PMC: 9221259. DOI: 10.3390/brainsci12060796.

Spontaneous Cerebrospinal Fluid Rhinorrhea from a Prolactin-Secreting Pituitary Macroadenoma.

Patel A, Gozal Y, Abou-Al-Shaar H, Taussky P, Couldwell W Cureus. 2021; 13(2):e13111.

PMID: 33728130 PMC: 7935238. DOI: 10.7759/cureus.13111.

References

Colao A, Lombardi G . Growth-hormone and prolactin excess. Lancet. 1998; 352(9138):1455-61. DOI: 10.1016/S0140-6736(98)03356-X. View

Delgrange E, Trouillas J, Maiter D, Donckier J, TOURNIAIRE J . Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997; 82(7):2102-7. DOI: 10.1210/jcem.82.7.4088. View

Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M . Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004; 89(4):1704-11. DOI: 10.1210/jc.2003-030979. View

Hondo E, Kurohmaru M, Sakai S, Ogawa K, Hayashi Y . Prolactin receptor expression in rat spermatogenic cells. Biol Reprod. 1995; 52(6):1284-90. DOI: 10.1095/biolreprod52.6.1284. View

Costello L, Franklin R . Effect of prolactin on the prostate. Prostate. 1994; 24(3):162-6. DOI: 10.1002/pros.2990240311. View

De Rosa M, Zarrilli S, Vitale G, Di Somma C, Orio F, Tauchmanova L . Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab. 2004; 89(2):621-5. DOI: 10.1210/jc.2003-030852. View

Colao A, Di Sarno A, Cappabianca P, Briganti F, Pivonello R, Di Somma C . Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003; 148(3):325-31. DOI: 10.1530/eje.0.1480325. View

Winters S . Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J Androl. 1991; 12(3):185-90. View

Manandhar M, Thomas J . Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro. Invest Urol. 1976; 14(1):20-2. View

10.

de Rosa M, Colao A, Di Sarno A, Ferone D, Landi M, Zarrilli S . Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998; 138(3):286-93. DOI: 10.1530/eje.0.1380286. View

11.

Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly P . Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998; 19(3):225-68. DOI: 10.1210/edrv.19.3.0334. View

12.

Leonard M, Nickel C, Morales A . Hyperprolactinemia and impotence: why, when and how to investigate. J Urol. 1989; 142(4):992-4. DOI: 10.1016/s0022-5347(17)38964-4. View

13.

Giannini C, Scheithauer B, Lloyd R, Wollan P, Kovacs K, Stefaneanu L . Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc. 1998; 73(11):1046-52. DOI: 10.4065/73.11.1046. View

14.

Biller B, Molitch M, Vance M, Cannistraro K, Davis K, SIMONS J . Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996; 81(6):2338-43. DOI: 10.1210/jcem.81.6.8964874. View

15.

Colao A, Vitale G, Di Sarno A, Spiezia S, Guerra E, Ciccarelli A . Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab. 2004; 89(6):2770-5. DOI: 10.1210/jc.2003-032055. View

16.

Colao A, de Rosa M, Sarnacchiaro F, Di Sarno A, Landi M, Iervolino E . Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol. 1996; 135(5):548-52. DOI: 10.1530/eje.0.1350548. View

17.

Verhelst J, Abs R, Maiter D, Van den Bruel A, Vandeweghe M, Velkeniers B . Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999; 84(7):2518-22. DOI: 10.1210/jcem.84.7.5810. View